Newswire (Published: Friday, July 7, 2017, Received: Thursday, June 29, 2017, 9:59:17 PM CDT)

Word Count: 516

Study Results from Massachusetts General Hospital Broaden Understanding of Prostate Cancer (Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic ...)

By a News Reporter-Staff News Editor at Drug Week -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Boston, Massachusetts, by NewsRx editors, research stated, "In the COU-AA-302 trial, abiraterone acetate plus prednisone significantly increased overall survival for patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC). Limited information exists regarding response to subsequent androgen signaling-directed therapies following abiraterone acetate plus prednisone in patients with mCRPC."

Our news journalists obtained a quote from the research from Massachusetts General Hospital, "We investigated clinical outcomes associated with subsequent abiraterone acetate plus prednisone (55 patients) and enzalutamide (33 patients) in a post hoc analysis of COU-AA-302. Prostate-specific antigen (PSA) response was assessed. Median time to PSA progression was estimated using the Kaplan-Meier method. The PSA response rate (>= 50% PSA decline, unconfirmed) was 44% and 67%, respectively. The median time to PSA progression was 3.9 mo (range 2.6-not estimable) for subsequent abiraterone acetate plus prednisone and 2.8 mo (range 1.8-not estimable) for subsequent enzalutamide. The majority of patients (68%) received intervening chemotherapy before subsequent abiraterone acetate plus prednisone or enzalutamide. While acknowledging the limitations of post hoc analyses and high censoring (>75%) in both treatment groups, these results suggest that subsequent therapy with abiraterone acetate plus prednisone or enzalutamide for patients who progressed on abiraterone acetate is associated with limited clinical benefit. Patient summary: This analysis showed limited clinical benefit for subsequent abiraterone acetate plus prednisone or enzalutamide in patients with metastatic castration-resistant prostate cancer following initial treatment with abiraterone acetate plus prednisone."

According to the news editors, the research concluded: "This analysis does not support prioritization of subsequent abiraterone acetate plus prednisone or enzalutamide following initial therapy with abiraterone acetate plus prednisone."

For more information on this research see: Clinical Outcomes from Androgen Signaling-directed Therapy after Treatment with Abiraterone Acetate and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Post Hoc Analysis of COU-AA-302. European Urology, 2017;72(1):10-13. European Urology can be contacted at: Elsevier Science Bv, PO Box 211, 1000 Ae Amsterdam, Netherlands. (Elsevier - www.elsevier.com; European Urology - www.journals.elsevier.com/european-urology/)

Our news journalists report that additional information may be obtained by contacting M.R. Smith, Massachusetts General Hospital, Boston, MA 02114, United States. Additional authors for this research include F. Saad, D.E. Rathkopf, P.F.A. Mulders, J.S. de Bono, E.J. Small, N.D. Shore, K. Fizazi, T. Kheoh, J.H. Li, P. De Porre, M.B. Todd, M.K. Yu and C.J. Ryan (see also Oncology - Prostate Cancer).

Keywords for this news article include: Boston, Massachusetts, United States, North and Central America, Prostate-Specific Antigen, Adrenal Cortical Steroids, Enzymes and Coenzymes, Drugs and Therapies, Prostatic Neoplasms, Prednisone Therapy, Pharmaceuticals, Glucocorticoids, Prostate Cancer, Androgens, Oncology, Hormones, Massachusetts General Hospital.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Industries

Healthcare
      Healthcare Facilities
            Hospitals

Places

Central America
North America
Western Europe
Netherlands
United States
Americas
Europe
Massachusetts
Amsterdam
Boston

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Health Sciences
            Medical Research
                  Clinical Outcomes
      Medical Specialties and Practices
            Urology
      Treatments and Therapies
            Chemotherapy